Resolvins of the D-series are specialized pro-resolving lipid mediators that regulate cellular response by orchestrating resolution networks involved in host responses to injury and infection. Here, endogenous resolvin D4 was identified in human tissues and found to persist late into the resolution phase of acute murine Staphylococcus aureus infections. Completion of the first total synthesis of resolvin D4 established the absolute stereochemical configuration of RvD4 confirmed by matching with endogenous RvD4 from resolving exudates in dorsal pouch S. aureus infections. In vivo, RvD4 (ng/mouse) reduced neutrophilic infiltration (~40%) and enhanced uptake of apoptotic PMN (51%) by human dermal fibroblasts at concentrations as low as 0.1 nM. These results establish the complete stereochemistry of RvD4 as 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z-hexaenoic acid and its novel pro-resolving actions in S. aureus infections as well as its potent ability to stimulate clearance of apoptotic cells by skin fibroblasts.
1
. Lipid mediators play key roles in regulating cytokine and chemokine production orchestrating the host response to injury and infection 2, 3 . The resolution phase lipid mediators, in addition to regulating leukocytic infiltration, also promote clearance of apoptotic cells, debris and bacteria (reviewed in ref. 1). Chronic inflammation is now thought to arise from a potential failure to resolve local inflammation and is linked with several conditions including rheumatoid arthritis, cardiovascular disease and infection 1, 4 . Resolution mediator networks actively shut down these pathways and regulate pro-resolving pathways that may in theory allow for disease prevention via resolution pharmacology and therapeutic strategies. Docosahexaenoic acid (DHA) is enriched in the brain, skin, central nervous system and eye. Appropriate consumption of DHA is linked with several wide-ranging effects on health and disease 5 . Towards appreciating the mechanisms underlying DHA impact, a family of DHA-derived local mediators termed D-series resolvins with unique biological activity and temporal profiles were identified during the resolution phase of acute inflammation. This family of autacoids is positioned at the nexus between a host's early response to inflammatory challenge and resolution pathways where the beginning or initiating programs signal the end or termination 1 . Establishing the complete stereochemistry of each specific SPM has permitted confirmation of their potent actions as well as determination of their novel specific biological actions including organ protection, tissue remodeling and microbial containment 1, 6 . From the resolvin (resolution phase interaction products) D series, the absolute stereochemistries of RvD1 (7S,8R,17S-trihydroxydocosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid), RvD2 (7S,16R,17S-trihydroxydocosa-4Z,8E,10Z,12E,14E,19Z-hexaenoic acid), and recently RvD3 (4S,11R,17S-trihydroxydocosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic acid), were each established along with select potent biological actions (for example, see ref. 7) . As originally described as the biological isolate, RvD4 possesses potent biological actions that include reducing neutrophilic infiltration, inhibiting glial cell cytokine production and regulating leukocyte diapedesis at concentrations as low as 1 nM 8 . Biologically isolated RvD4 also potently reduces recruitment of neutrophils in murine peritonitis and dorsal skin pouch in response to either opsonized zymosan or TNF-α 9 . In addition, RvD4 is also produced during ischemic kidney injury and exerts organ protection 10 .
. The structure of RvD4 was originally deduced based on biosynthetic evidence as well as liquid chromatography-tandem mass spectrometry (LC-MS-MS) and GC-MS metabololipidomic profiling of the bioactive compound from exudates and human leukocytes, which did not allow for establishing the double-bond triene geometry as well as the chirality of the alcohol at the 5 position. In the present report using material obtained by a total organic synthesis approach, we establish the complete stereochemistry of RvD4 as 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z-hexaenoic acid, confirm its potent biological actions and establish its new specific pro-resolving action in dermal inflammation and infection.
Results
RvD4 is produced in bioactive levels during S. aureus infection. To identify relevant SPMs with protective actions during the resolution programme we used a well-established dorsal pouch model for murine S. aureus skin infection 6 with focus on the endogenous formation and appearance of Resolvin D4 (Fig. 1) . Inoculation of S. aureus at 10 5 c.f.u. gave a self-limited inflammatory response with polymorphonuclear leukocyte (PMN) numbers reaching a maximum at 12 hr (T max ), followed by a sharp decline and return to basal levels by 24 hr. At 12 hr, monocytes/macrophages gave a more persistent presence and remained elevated throughout the resolution phase into the later time points ( Fig. 2A) , consistent with their role in clearance of apoptotic PMN and cellular debris 8, 11 . In this time course, the LM and SPM profiles from infectious exudates were monitored using LC-MS-MS-based lipid mediator metabololipidomics. The inflammation initiating prostaglandins and leukotrienes LTB 4 , PGE 2 and PGD 2 increased sharply in response to a bacterial inoculation followed by a return to basal levels (Fig. 2B,C) . In these infectious purulent exudates we normalized the recovery based on individual lavage volume to determine the temporal profile of the D-series resolvins and found them present in low picomolar concentrations. RvD1 and RvD2 reached a maximum presence at 12 hr. RvD3 was observed at low levels throughout the time course of self-limited infection whereas RvD4 gave a unique pattern with its production persisting late into the resolution phase. These results suggest that RvD4 is constituently present and is differentially regulated and produced to regulate processes in the resolution of infection (Fig. 2D,E) .
Total organic synthesis of RvD4. To establish the complete stereochemistry for RvD4 and assign the double bond geometry around C7 to C11 and the chirality of the alcohol at the C5 position, we employed a total organic synthesis approach that was also used in establishing the complete stereochemistry for other SPM 12 . Along these lines the complete total synthesis of RvD4 was accomplished using a 22-step total organic synthetic scheme, to afford stereochemically pure 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z-hexaenoic acid, RvD4, shown in Fig. 3A . The hydroxyl groups positioned at the 4S, 5R carbon positions proved similarly to be a problematic complication in which the ester precursor rearranged to form a mixture of the ester as well as the 5-and 6-membered lactone, as observed similarly with the synthesis of RvD3 12 .
With these aforementioned challenges in mind we began our synthesis with the ring opening of chirally pure d-erythrose to set the 4S, 5R hydroxyl groups in the proposed stereoconfiguration. Next, we took advantage of a Wittig coupling to form the carbon-carbon bond at the 6-position between the Wittig salt and aldehyde and through additional manipulation built the conjugated triene system. The 17S-hydroxy position was set in place through a ring opening of chiral R-glycidol. The final carbon-carbon bond was formed through a copper-mediated cross coupling of an allylic-bromide with terminal alkyne C11 to afford the protected bis-acetylenic precursor in good yield. Because of the sensitive nature of each metabolite, RvD4 at this stage required careful handling. The bis-acetylenic precursor was reduced prior to the deprotection; however, Zn/Cu/Ag hydrogenation was too mild in the presence of bulky protecting groups. Therefore, Lindlar catalyst was employed and subsequent desilylation allowed for the synthesis of the final compound 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z-hexaenoic acid without decomposition. The absolute structure was confirmed by 2D 1 H-1 H nuclear magnetic resonance (NMR) spectroscopy for full proton assignment (Fig. 3B) . Matching of endogenous RvD4 with synthetic materials. We next matched the physical properties of the material obtained by total organic synthesis to that of endogenous RvD4. Our first criterion for the matching of authentic material with synthetic compound was by retention time. The chromatographic signature of both the endogenous and synthetic material demonstrated identical retention profiles by reverse phase high pressure liquid chromatography (HPLC) with a sharp peak eluting with retention time (T R ) of 12.2 min (Fig. 4A,B) . Coinjection of the authentic RvD4 isolated from purulent inflammatory exudates with synthetic compound confirmed that these products co-eluted (Fig. 4C) .
Further validation of synthetic material was confirmed by assessing the UV absorbance profile and tandem mass spectrometry (MS-MS) patterns. The synthetic material displayed UV absorbance profile with a triplet band of absorption, λ max MeOH , at 275 nm and shoulders at 266 and 285 that is characteristic of a triene conjugated double-bond system 1 . The synthetic material also gave a broad shoulder with absorption λ max MeOH at ~226 nm ( (Fig. 4D ,E). To place RvD4 within the D-series resolvins we profiled the infectious exudates and found that RvD4 eluted last of the trihydroxyl resolvin family giving it the most lipophilic characteristic of the four (Fig. 4F ).
RvD4 stops neutrophil infiltration in sterile peritonitis and S. aureus skin infection. We next sought to confirm the potent anti-inflammatory and pro-resolving actions of RvD4 with synthetic material. First we assessed its actions in regulating the acute inflammatory response initiated by zymosan A in a peritonitis model. Zymosan administration via i.p. injection gave rapid PMN infiltration into the peritoneal cavity at 4 hr. Shown on the representative dot plots and bar graphs, RvD4 at 10 ng/mouse decreased percent of PMN, giving ~31% reduction at 4 hours (Fig. 5A ). For comparison, administration of an equal amount of the . Total synthesis and characterization of Resolvin D4. Synthetic RvD4 was accomplished by total organic synthesis from chirally pure starting materials prepared by multi-step total organic synthesis and characterized using NMR spectroscopy. (A) Synthetic precursors were prepared from enantiomerically pure commercially available starting materials and coupled using carbon-carbon bond coupling reactions between precursor C 1 -C 6 in (blue), C 7 -C 11 (in red), and C 12 -C 22 (in black) to ensure absolute regio-and stereochemical assignment; (B) Double-bond geometry was assigned using 2-dimensional 1 H-1 H NMR using a Varian NMRS 600 MHz NMR spectrometer at 25 °C on a 5 mm Triple Resonance PFG 1 H probe and referenced to the CD 3 OD internal standard. The rainbow plot depicts positive contours of cross peaks along the diagonal axis allowing for the full and detailed proton assignment. The zoomed-in region highlights the Z/E olefinic protons H 6 potent immunoresolvent RvD3 7 also gave ~44% reduction in PMN infiltration. These results confirm the potent pro-resolving anti-inflammatory properties initially described for the bioactive RvD4 8 with synthetic material. With the biological activity of RvD4 confirmed, we next assessed its in vivo actions in S. aureus-mediated infection probing its action as well as temporal formation. To determine its role in bacterial killing and host protection during S. aureus infections, RvD4 was administered at 200 ng/mouse concomitantly with a self-limited bacterial inoculation (10 5 c.f.u) into the dorsal pouch of male FVB mice. Resolution indices were then measured. RvD4 potently reduced neutrophilic infiltration by ~40% at T max (12 h ) and shortened the resolution interval in mice treated with RvD4 from 6 to 3 hr (Fig. 5B) . Analysis by histochemical staining of dorsal pouch lining from mice administered vehicle or RvD4 gave lower PMN levels in the cavity in mice treated with RvD4 (Fig. 5C ). Treatment with RvD4 also significantly lowered bacterial counts when compared to vehicle control (Fig. 5D ). In addition, RvD4 enhanced the phagocytosis of S. aureus by isolated mouse macrophages by ~40% at 10nM (data not shown). RvD4 also regulated inflammation-initiating eicosanoids in the inflammatory exudates including LTB 4 and PGD 2 by 68 and 48% respectively, demonstrating potent anti-inflammatory actions in vivo (Fig. 5E-G) . RvD4 exerts pro-resolving actions with human neutrophils and macrophages. To further elucidate its host-protective actions, we sought to establish the potent anti-inflammatory and pro-resolving actions of RvD4 with isolated human leukocytes. RvD4 (0.01 nM to 10 nM) promoted bacterial phagocytosis by human macrophages (12-18%) to a similar extent as the pro-resolving mediator RvD3 (Fig. 6A) . RvD4 also promoted the phagocytosis of opsonized zymosan A at concentrations as low as 0.1-10 nM, significantly enhancing macrophage uptake by 40-60% above vehicle controls (Fig. 6B) .
The clearance of apoptotic PMN during inflammation is a cellular hallmark in resolution 1, 14 . To determine RvD4's role in the clearance of apoptotic neutrophils we assessed whether RvD4 promoted macrophage efferocytosis. RvD4 statistically significantly increased macrophage efferocytosis of apoptotic neutrophils by 40-50% at concentrations as low as 0.1-10 nM (Fig. 6C) . These results suggest that RvD4 enhances human macrophage functions in clearing cellular debris and microbial particles. Together these results provide evidence that RvD4 is pro-resolving with human phagocytes.
RvD4 exerts pro-resolving actions with human fibroblasts: Comparison with RvD1 and
MaR1. Given that RvD4 displayed potent pro-resolving actions in skin infection, we investigated whether it also acts on human dermal fibroblasts. RvD4 potently promoted the clearance of apoptotic PMN by human fibroblasts (Fig. 6D ) by ~59% at 1 nM. Of the SPM tested, RvD4 and RvD1 at 1 nM gave the highest increase in apoptotic cell uptake (~52 and 57%). These findings demonstrate new action of SPM such as RvD1 and MaR1 (7R,14S-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid) in resolution and that RvD4 displays potent actions with human dermal fibroblasts (Fig. 6E ). human breast milk 16 as well as murine spleen, brain and sardines (Table 1) . The presence of endogenous RvD4 in these samples at picogram levels (10-100 pg) suggests a utility in the evolutionary conservation in structure function across species associated with its role in the resolution process.
RvD4 identification in tissue in

Discussion
In the present report we establish the complete stereochemical assignment of RvD4 as 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z-hexaenoic acid by matching endogenous material isolated from purulent inflammatory exudates with synthetic compound (Fig. 4) made by total organic synthesis (Fig. 3) . RvD4 was temporally regulated during S. aureus infection as well as remained at bioactive levels (~ pM) in the late stages of resolution (Fig. 2) . Administration of RvD4 in vivo counter regulated inflammatory initiating eicosanoids in S. aureus infection and shortened resolution indices during infection (Fig. 5) , concepts on which the edifice of resolution is based. Administration of RvD4 in both sterile inflammation and microbial infection gave a reduction in neutrophil recruitment in vivo (Figs 5 and 6 ). RvD4 also enhanced macrophage responses with human macrophages and enhanced fibroblast responses with human fibroblasts in efferocytosis of apoptotic PMN and sterile zymosan (Fig. 6) . Furthermore RvD4 was found to be present in a number of tissues across species suggesting its utility through evolutionary conservation (Table 1) .
The biosynthesis of this family of compounds by lipoxygenase enzymes affords their unique structures and function. RvD4 and its congener RvD3 are formed via a common 4, 5-epoxide involving a second oxygenation pathway by lipoxygenase enzymes. The divergence between RvD3 and RvD4 occurs from the insertion of water by enzymatic hydrolysis at the C11 and C5 position through a carbocation intermediate to afford RvD3 and RvD4, respectively (Fig. 1) . Both compounds have distinct behaviors based on their arrangement of chiral hydroxyl stereocenters and double-bond triene-diene configuration giving them each a distinct activity profile and set of physical characteristics such as absorbance and retention time. Synthetic RvD3 demonstrated greater potency in a mouse peritonitis model (Fig. 5) while synthetic RvD4 significantly increased efferocytosis in human fibroblasts by promoting the clearance of apoptotic PMN, while RvD3 was not significant (Fig. 6) .
Resolvins can alleviate both the bacterial burden in a skin S. aureus infection as well as in lung infection models 6, 17 . Resolvins are produced and act locally in a time-dependent fashion to intercede with an overbearing neutrophilic response that can lead to chronic inflammation, tissue fibrosis, and scarring. Antibiotic-resistant S. aureus skin infections are widespread and a leading cause of hospital-acquired infection 6 . The acute inflammatory response involves a number of inflammation-initiating chemical mediators including thromboxanes, prostaglandins and leukotrienes as well as cytokines and chemokines. The D-series resolvins arbitrate this interaction by shutting down proinflammatory pathways and turning on resolution networks 8, 11, 18, 19 . In the S. aureus infection model, RvD1 and RvD2 levels traced with the eicosanoids followed by a temporally distinct response of Resolvin D3 and D4 at later time points, thus suggesting differential roles in the 7,8 vs. 4,5 epoxide pathway shared by RvD4 and RvD3 during late-stage clearance through phagocytosis of foreign bacteria and apoptotic PMN by macrophages and dermal fibroblasts (Fig. 6) . Administration of RvD4 in vivo stopped leukocyte influx to the site of infection in the dorsal pouch cavity as well as the inflammation-initiating eicosanoids by reducing levels of PGD 2 and LTB 4 .
Earlier work has shown that SPM actions are not limited to leukocytes but can stimulate endothelial cell-leukocyte interactions, suggesting a more prominent role in the resolution phase. Fibroblasts are known to be a critical component in wound healing and tissue remodeling for their restorative properties in supporting the structural framework for tissue and repair 20, 21 . Lung fibroblasts and periodontal ligament fibroblasts have been shown to respond to SPMs under smoke-induced lung inflammation 22 and periodontal disease 23 , respectively. Dermal fibroblasts were found to phagocytize apoptotic PMN and opsonized beads as previously reported in refs 24 and 25, and this action was enhanced by RvD4, providing a novel mechanism of action in the resolution of dermal infectious inflammation. The role SPM play in signaling dermal fibroblasts during resolution has not been investigated before. We investigated RvD4's role in signaling dermal fibroblast clearance of apoptotic PMN and found RvD4 actively promotes phagocytosis at subnanomolar concentrations, suggesting it as a critical player in the resolution regiment of this potent class of autacoids.
In summation, the present findings report the complete stereochemistry of RvD4, endogenous production of RvD4 during infection, RvD4's regulation of leukocyte recruitment in sterile inflammation and infection, counter-regulation of eicosanoids, phagocyte-directed action with human macrophages (defining its pro-resolving actions), increase of fibroblast phagocytosis as well as RvD4 identification across several species. These findings Table 1 . Endogenous production of RvD1-4. Endogenous levels of resolvins in mouse tissue, human serum, plasma and sardines using LM metabololipidomics. Results are mean ± SEM, n = 3 exudates. Q1 (parent ion) and Q3 (diagnostic daughter ion). asterisk (*) = below limit, limit ~ 0.1 pg in matrix
D-Series metabolome
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suggest RvD4 plays a pivotal role(s) in infectious resolution as well as gives insight into its temporal vignette in the endogenous production of these potent SPM-autacoids during resolution and return to homeostasis.
Significance
These results establish RvD4 stereochemistry and role in host protection and resolution of inflammation during bacterial infection on specific target cell types including neutrophils and macrophages. RvD4 diminishes inflammation by promoting clearance of a bacterial burden and promotes the efferocytosis of apoptotic PMN. For the first time an SPM was shown to have a direct proresolving action on a new target cell type, human dermal fibroblasts, where RvD4 potently stimulates phagocytosis and efferocytosis of cellular debris and apoptotic neutrophils. The complete stereochemical assignment of RvD4 with its synthetic precursor was confirmed by matching both physical properties as well as biological actions to confirm the complete stereochemical assignment, which now opens a new path for therapeutic developments based on RvD4 structure and action. The identification of endogenous D-series resolvins and RvD4 displays a unique spatio-temporal ensemble and is produced at biologically relevant levels during S. aureus-initiated infection suggesting an endogenous host defense mechanism triggering resolution and host protection during infectious inflammation. These results from RvD4 provide structural evidence for a new approach to host-directed therapies that now take into account the role of fibroblasts in resolution as well as infection.
Methods
Materials. RPMI 1640 and DPBS (with or without calcium and magnesium) were purchased from Lonza (Hopkinton, MA, USA). Ficoll-Histopaque 1077-1, lipopolysaccharide (LPS) and zymosan A were obtained from Sigma-Aldrich (St. Louis, MO, USA). Human recombinant granulocyte-monocyte colony stimulating factor (GM-CSF), macrophage colony-stimulating factor, interferon γ (IFN-γ ) and interleukin-4 were purchased from R&D Systems (Minneapolis, MN, USA). Fetal calf sera, ampicillin and bac-to-bac baculovirus expression system were from Invitrogen (Grand Island, NY, USA). FITC rat anti-mouse Ly6G (clone IAS) and purified rat anti-mouse CD16/32 (mouse BD Fc block) were purchased from BD Biosciences (San Jose, CA), and PE rat antimouse F4/80 (clone BM8) and PerCP/Cy5.5 rat anti-mouse CD11b (clone Mac-1) were purchased from eBioscience (San Diego, CA). C18 SPE columns were from Waters (Milford, MA, USA). Poroshell C18 columns were from Phenomenex; fluorescently conjugated zymosan A was from Invitrogen. Dorsal skin pouch. Mice were anesthetized with isoflurane, and 3.0 ml of sterile air was injected subcutaneously on days 0 and 3 between the shoulders and into the back of male mice. On day 6, S. aureus (10 5 c.f.u./mouse) was administered by intra-pouch injection in combination with either RvD4 (200 ng/mouse) or sterile saline. No apparent changes were observed in animal behavior, and mice were euthanized and lavages were collected at designated time points (4, 12, 24, 36, 48 and 72 hr) with 3 mL DPBS −/− . Leukocytes were enumerated and differential counts conducted by flow cytometry and graphed by curve smoothing. Aliquots of lavage were serial diluted and plated on agar plates and cultured overnight at 37 °C to determine bacterial counts. Skin punch biopsies were collected and stained for hematoxylin-eosin staining.
Murine peritonitis. 1 mg/ml of zymosan was injected i.p. in parallel with RvD3 (10 ng), RvD4 (10 ng), or vehicle in 100 μ l saline. At 4 h, peritoneal lavages were collected and cell counts enumerated by flow cytometry. 
Statistics.
Results are expressed as means ± SEM. Comparison between two groups was analyzed using Student's t test and between multiple groups using ANOVA. Statistical significance was considered to be P < 0.05.
